Academia and Industry: Us vs Them
Is ensuring integrity within the clinical trials enterprise, as some claim, beyond the reach of industry?
In his July Clinical Trials Insight column, Kenneth Getz examines the recent harsh criticisms by academia aimed at industry research. Although for years academia has considered itself above industry, as of late some academics are taking their bias to the extreme, “calling for industry to have no involvement in clinical research,” according to Getz. They believe that the problems within the enterprise, such as conflicts of interest or unethical practices, are isolated to industry and suggest that only academic-based professionals can ensure integrity.
Check out how Getz responds to this view in “Are Academia and NIH Bastions of Integrity” and then let us know how you feel about it in an email to actspecialprojects@advanstar.com.
Responses and discussion regarding this topic will appear in a future blog post on this Web site.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
